So far, so good’; Results of first two cohorts reported as third and final cohort is ongoing PITTSBURGH, February 20, 2023 – A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women. The ongoing Phase IIIb study, known as DELIVER, or MTN-042, was designed to evaluate the safety and…
Read More